JPWO2025105377A5 - - Google Patents

Info

Publication number
JPWO2025105377A5
JPWO2025105377A5 JP2025534818A JP2025534818A JPWO2025105377A5 JP WO2025105377 A5 JPWO2025105377 A5 JP WO2025105377A5 JP 2025534818 A JP2025534818 A JP 2025534818A JP 2025534818 A JP2025534818 A JP 2025534818A JP WO2025105377 A5 JPWO2025105377 A5 JP WO2025105377A5
Authority
JP
Japan
Prior art keywords
epstein
barr virus
disease
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025534818A
Other languages
English (en)
Japanese (ja)
Other versions
JP7791559B2 (ja
JPWO2025105377A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2024/040210 external-priority patent/WO2025105377A1/ja
Publication of JPWO2025105377A1 publication Critical patent/JPWO2025105377A1/ja
Publication of JPWO2025105377A5 publication Critical patent/JPWO2025105377A5/ja
Application granted granted Critical
Publication of JP7791559B2 publication Critical patent/JP7791559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025534818A 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤 Active JP7791559B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023193086 2023-11-13
JP2023193086 2023-11-13
PCT/JP2024/040210 WO2025105377A1 (ja) 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤

Publications (3)

Publication Number Publication Date
JPWO2025105377A1 JPWO2025105377A1 (https=) 2025-05-22
JPWO2025105377A5 true JPWO2025105377A5 (https=) 2025-10-15
JP7791559B2 JP7791559B2 (ja) 2025-12-24

Family

ID=95742274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025534818A Active JP7791559B2 (ja) 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤

Country Status (2)

Country Link
JP (1) JP7791559B2 (https=)
WO (1) WO2025105377A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181118B1 (en) * 2015-12-14 2019-02-13 Warszawski Uniwersytet Medyczny Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies

Similar Documents

Publication Publication Date Title
JP2023526836A5 (https=)
Albina et al. Interferon-α response to swine arterivirus (PoAV), the porcine reproductive and respiratory syndrome virus
JP2009535352A5 (https=)
JP2010512307A (ja) 抗ウイルス組成物及び使用方法
CN113304166A (zh) 核苷类化合物在治疗冠状病毒感染性疾病中的用途
Bonville et al. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents
JP2017514911A5 (https=)
LASKIN Acyclovir and suppression of frequently recurring herpetic whitlow
Szaniawski et al. Senotherapeutics for HIV and aging
JP2023528561A5 (https=)
JP2023537229A5 (https=)
JPWO2025105377A5 (https=)
Sridevi et al. Convalescent plasma therapy for prophylaxis and treatment of COVID-19: A systematic research of facts and files, a narrative review
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
CN113209087A (zh) 一种抑制冠状病毒的药物组合物及其用途
Nagao et al. Oral-mucosal administration of IFN-α potentiates immune response in mice
Zeuzem et al. 78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis
JP2021523129A5 (https=)
SWANN Epidemic pleurodynia, orchitis, and myocarditis in an adult due to Coxsackie virus, group B, type 4
RU2297846C2 (ru) Способ лечения очагового и инфильтративного туберкулеза легких
CN106943416A (zh) 药物组合物及其在制备治疗肺炎或/和增强上呼吸道感染中自然杀伤细胞活性药物中的应用
JP2002527397A5 (https=)
Gaia et al. Lamivudine in anti-HBeAg positive chronic hepatitis B: response after one year of treatment
Yurko et al. Clinical and laboratory characteristics of infectious mononucleosis caused by Epstein-Barr, effectiveness of treatment methods
Scotto et al. Treatment with ribavirin+ alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results